U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H14N4O2
Molecular Weight 174.201
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARGININE

SMILES

N[C@@H](CCCNC(N)=N)C(O)=O

InChI

InChIKey=ODKSFYDXXFIFQN-BYPYZUCNSA-N
InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1

HIDE SMILES / InChI

Molecular Formula C6H14N4O2
Molecular Weight 174.201
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.

CNS Activity

Curator's Comment: L-Arginine has the ability to cross the blood brain barrier.

Originator

Curator's Comment: Arginine was first isolated from a lupin seedling extract in 1886 by the German chemist Ernst Schultze.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q5T6X5
Gene ID: 222545.0
Gene Symbol: GPRC6A
Target Organism: Homo sapiens (Human)
44.1 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

9.9705602E10
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

9.9705602E10
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

9.9705602E10
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

9.9705602E10
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
310 μM
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
6219 μM
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
882 μM
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
24788 M × min
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
265435 M × min
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
38223 M × min
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
77.5 min
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
41.6 min
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
59.6 min
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
ARGININE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis...
AEs leading to
discontinuation/dose reduction:
Cardiopulmonary arrest
Metabolic acidosis (acute)
Hyponatremia (severe)
Sources: Page: p.621
200 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg/kg, 3 times / day
Sources: Page: p.63
unhealthy, 24
n = 11
Health Status: unhealthy
Condition: Cystic fibrosis
Age Group: 24
Sex: M+F
Population Size: 11
Sources: Page: p.63
15 g 2 times / day multiple, oral
Studied dose
Dose: 15 g, 2 times / day
Route: oral
Route: multiple
Dose: 15 g, 2 times / day
Sources: Page: p.1
healthy, 34 ± 2.6
n = 12
Health Status: healthy
Condition: Dietary supplementation
Age Group: 34 ± 2.6
Sex: M+F
Population Size: 12
Sources: Page: p.1
7 g 3 times / day multiple, oral
Studied dose
Dose: 7 g, 3 times / day
Route: oral
Route: multiple
Dose: 7 g, 3 times / day
Sources: Page: p.200
unhealthy, 43± 16
n = 10
Health Status: unhealthy
Condition: Hypercholesterolaemia
Age Group: 43± 16
Sex: M+F
Population Size: 10
Sources: Page: p.200
DLT: Gastrointestinal discomfort...
Dose limiting toxicities:
Gastrointestinal discomfort (20%)
Sources: Page: p.200
AEs

AEs

AESignificanceDosePopulation
Cardiopulmonary arrest Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Metabolic acidosis acute
Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Hyponatremia severe
Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Gastrointestinal discomfort 20%
DLT
7 g 3 times / day multiple, oral
Studied dose
Dose: 7 g, 3 times / day
Route: oral
Route: multiple
Dose: 7 g, 3 times / day
Sources: Page: p.200
unhealthy, 43± 16
n = 10
Health Status: unhealthy
Condition: Hypercholesterolaemia
Age Group: 43± 16
Sex: M+F
Population Size: 10
Sources: Page: p.200
PubMed

PubMed

TitleDatePubMed
Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans.
2000 Dec
Two novel mutations (Y141H; C214Y) and previously published mutation (R142W) in the RDS-peripherin gene in autosomal dominant macular dystrophies in Spanish families.
2001
A rare case of complete human erythrocyte AMP deaminase deficiency due to two novel missense mutations in AMPD3.
2001
Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes.
2001
Renal response during acute unilateral ureteral obstruction in rats.
2001
The dialytic failure of the peritoneal membrane.
2001
Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability.
2001 Apr 13
Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF.
2001 Apr 20
An intrahelical salt bridge within the trigger site stabilizes the GCN4 leucine zipper.
2001 Apr 27
Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases.
2001 Apr 6
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.
2001 Feb
Amino acid residues outside of the pore region contribute to N-type calcium channel permeation.
2001 Feb 23
The nutritional management of urea cycle disorders.
2001 Jan
Current strategies for the management of neonatal urea cycle disorders.
2001 Jan
Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells.
2001 Jan
Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro.
2001 Jan
Effect of AVT antisense oligodeoxynucleotides on AVT release induced by hypertonic stimulation in chicks.
2001 Jan
Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia.
2001 Jan
Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme.
2001 Jan
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.
2001 Jan
An extended hydrophobic interactive surface of Yersinia pestis Caf1M chaperone is essential for subunit binding and F1 capsule assembly.
2001 Jan
Increased colocalization of corticotropin-releasing factor and arginine vasopressin in paraventricular neurones of the hypothalamus in lactating rats: evidence from immunotargeted lesions and immunohistochemistry.
2001 Jan
A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats.
2001 Jan
Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension.
2001 Jan
Relationship between flow rate and NO production in postnatal mesenteric arteries.
2001 Jan
Altered TNF-alpha, glucose, insulin, and amino acids in islets of Langerhans cultured in a microgravity model system.
2001 Jan
Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells.
2001 Jan
Buffering action of endogenous nitric oxide on the adrenocortical secretagogue effect of endothelins in the rat.
2001 Jan
In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells.
2001 Jan
The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets.
2001 Jan
Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70.
2001 Jan 1
Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain.
2001 Jan 1
Substitution of Asp114 or Arg116 in the fingers domain of moloney murine leukemia virus reverse transcriptase affects interactions with the template-primer resulting in decreased processivity.
2001 Jan 12
Amino acid residues in ribonuclease MC1 from bitter gourd seeds which are essential for uridine specificity.
2001 Jan 16
Structure and organization of bacteriophage Pf3 probed by Raman and ultraviolet resonance Raman spectroscopy.
2001 Jan 16
Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine.
2001 Jan 19
Site-specific single amino acid changes to Lys or Arg in the central region of the movement protein of a hybrid bromovirus are required for adaptation to a nonhost.
2001 Jan 5
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum.
2001 Jan 5
The role of nitric oxide in bradycardia of rats with obstructive cholestasis.
2001 Jan 5
C60-Fullerene monomalonate adducts selectively inactivate neuronal nitric oxide synthase by uncoupling the formation of reactive oxygen intermediates from nitric oxide production.
2001 Jan 9
Translocation of jellyfish green fluorescent protein via the Tat system of Escherichia coli and change of its periplasmic localization in response to osmotic up-shock.
2001 Mar 16
The molecular mechanism for the genetic disorder familial defective apolipoprotein B100.
2001 Mar 23
Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages.
2001 Mar 30
Scanning mutagenesis reveals roles for helix n of the bacteriophage T7 RNA polymerase thumb subdomain in transcription complex stability, pausing, and termination.
2001 Mar 30
Substrate-binding clusters of the K+-transporting Kdp ATPase of Escherichia coli investigated by amber suppression scanning mutagenesis.
2001 Mar 30
Peptide leucine arginine, a potent immunomodulatory peptide isolated and structurally characterized from the skin of the Northern Leopard frog, Rana pipiens.
2001 Mar 30
Identification of the collagen-binding site of the von Willebrand factor A3-domain.
2001 Mar 30
The modulation of oxygen radical production by nitric oxide in mitochondria.
2001 Mar 9
The fission yeast TOR homolog, tor1+, is required for the response to starvation and other stresses via a conserved serine.
2001 Mar 9
Rare somatic p53 mutation identified in breast cancer: a case report.
2001 Mar-Apr
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride. https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration: Oral
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:28 UTC 2023
Edited
by admin
on Fri Dec 15 15:02:28 UTC 2023
Record UNII
94ZLA3W45F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARGININE
EP   HSDB   II   INCI   INN   MART.   MI   USP   VANDF   WHO-DD  
INCI   INN  
Official Name English
ARG
Common Name English
ARGININE [HSDB]
Common Name English
arginine [INN]
Common Name English
ARGININE [EP IMPURITY]
Common Name English
L-ARGININE [FHFI]
Common Name English
ARGININE [MART.]
Common Name English
ARGININE [II]
Common Name English
Arginine [WHO-DD]
Common Name English
ARGININE [VANDF]
Common Name English
L-ARGININE
FCC   FHFI   USP-RS  
Systematic Name English
L-ARGININE [FCC]
Common Name English
ARGININE [USP MONOGRAPH]
Common Name English
L-ARGININE [USP-RS]
Common Name English
ARGININE [EP MONOGRAPH]
Common Name English
LYSINE ACETATE IMPURITY F [EP IMPURITY]
Common Name English
(S)-2-AMINO-5-((AMINOIMINOMETHYL)AMINO)PENTANOIC ACID
Systematic Name English
ARGININE [MI]
Common Name English
ARGININE [INCI]
Common Name English
NSC-206269
Code English
L-ARGININE [JAN]
Common Name English
Classification Tree Code System Code
LOINC 54092-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 27974-5
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 26985-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 55911-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 27296-3
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 32226-3
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 1895-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
DSLD 2368 (Number of products:1422)
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 32225-5
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 15136-5
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 47566-5
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
WHO-ATC B05XB01
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 16401-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 22656-3
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
DSLD 116 (Number of products:647)
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
FDA ORPHAN DRUG 785420
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 30062-4
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 43927-3
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 53398-4
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 47563-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 47568-1
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 47565-7
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 25861-6
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 47564-0
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 25322-9
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 13387-6
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 13708-3
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 53200-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 22697-7
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 25860-8
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 1891-1
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
JECFA EVALUATION L-ARGININE
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
NCI_THESAURUS C68442
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 1892-9
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 20637-5
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 41168-6
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 56672-9
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 75214-7
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 1893-7
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 1894-5
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 44299-6
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 47562-4
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
CFR 21 CFR 172.320
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 22727-2
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 15140-7
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
LOINC 47567-3
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
Code System Code Type Description
CHEBI
16467
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
SMS_ID
100000086598
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
INN
1711
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
MERCK INDEX
m2040
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY Merck Index
EVMPD
SUB20033
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
CHEBI
29952
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
FDA UNII
94ZLA3W45F
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
GRAS Notification (GRN No.)
317
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
HEALTH-CANADA NHP INGREDIENT RECORD
7274
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
NSC
206269
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
PUBCHEM
6322
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
JECFA MONOGRAPH
1426
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
NCI_THESAURUS
C62008
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
CHEBI
32682
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
EVMPD
SUB05560MIG
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
HEALTH -CANADA NHP INGREDIENT MONOGRAPH
124
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
MESH
D001120
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
DRUG BANK
DB00125
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
WIKIPEDIA
ARGININE
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
DAILYMED
94ZLA3W45F
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
ChEMBL
CHEMBL1485
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
RS_ITEM_NUM
1042500
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
RXCUI
1091
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY RxNorm
CHEBI
29016
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
CAS
74-79-3
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
HSDB
1429
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
EPA CompTox
DTXSID6041056
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-811-1
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
CHEBI
32696
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
GRAS Notification (GRN No.)
290
Created by admin on Fri Dec 15 15:02:28 UTC 2023 , Edited by admin on Fri Dec 15 15:02:28 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SUBSTRATE -> TARGET
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
PARENT -> CONSTITUENT ALWAYS PRESENT
ASSAY (HPLC)
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
PLASMA
METABOLITE -> PARENT
PLASMA
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (TLC)
EP
Related Record Type Details
ACTIVE MOIETY